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Abstract
Background: The role of Artificial intelligence (AI) which is defined as the ability of computers to perform tasks that
normally require human intelligence is constantly expanding. Medicine was slow to embrace AI. However, the role
of AI in medicine is rapidly expanding and promises to revolutionize patient care in the coming years. In addition, it
has the ability to democratize high level medical care and make it accessible to all parts of the world.
Main text: Among specialties of medicine, some like radiology were relatively quick to adopt AI whereas others
especially pathology (and surgical pathology in particular) are only just beginning to utilize AI. AI promises to play a
major role in accurate diagnosis, prognosis and treatment of cancers. In this paper, the general principles of AI are
defined first followed by a detailed discussion of its current role in medicine. In the second half of this
comprehensive review, the current and future role of AI in surgical pathology is discussed in detail including an
account of the practical difficulties involved and the fear of pathologists of being replaced by computer algorithms.
A number of recent studies which demonstrate the usefulness of AI in the practice of surgical pathology are
highlighted.
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Conclusion: AI has the potential to transform the practice of surgical pathology by ensuring rapid and accurate
results and enabling pathologists to focus on higher level diagnostic and consultative tasks such as integrating
molecular, morphologic and clinical information to make accurate diagnosis in difficult cases, determine prognosis
objectively and in this way contribute to personalized care.
Keywords: Artificial intelligence, Medicine, Pathology
Introduction
The role of Artificial intelligence (AI) in the field of
medicine is constantly expanding. AI promises to
revolutionize patient care in the coming years with the
aim of optimizing personalized medicine and tailoring it
to the use of individual patients. Medicine embraced AI
slowly. Some specialties such as radiology were quick to
adopt AI. Others like pathology are only now beginning
to utilize AI in clinical use. In this article, we will start
by describing the general principles of AI. We will then
analyze its current role in medicine in general by looking
at various examples of its applications in specialties such
as radiology and oncology. In the second half of this re-
view, we will discuss the current and expected future
role of AI in surgical pathology, the practical, financial
and regulatory difficulties involved, the future of the
microscope and the fear of pathologists of being re-
placed by computer algorithms. We will also discuss a
number of recent studies which highlight the usefulness
of AI in the practice of surgical pathology.
Main text
General principles and definitions
AI can be defined as the ability of computers to perform
tasks that normally require human intelligence. It refers
to the development and programming of computers and
devices having human-like characteristics which can per-
form diverse complex functions such as driving an auto-
matic car, diagnosing a medical condition, discovering
fraud and money laundering, interpreting legal advice,
proving mathematical theorems etc.
Machine learning (ML)
a subfield of AI, is defined as a computational system
based on a set of algorithms that attempts to analyze
vast and diverse data by using multiple layers of analysis.
There are a number of ways in which a computer can be
programmed to make intelligent judgments and it is es-
sential to use the right algorithms for specific purposes.
ML is one of the commonest AI techniques used for
processing big data. It is a self-adaptive system that pro-
vides increasingly better analysis and patterns with ex-
perience and newly added data. These techniques have
evolved hand – in – hand with the digital era which has
brought about an explosion of data in all forms from all
parts of the world. Enormous amount of data, known
simply as big data is easily and readily accessible and can
be shared through applications like cloud computing.
ML applies statistical methods to automatically learn
from data and experience without explicit instructions.
It has seen an explosion of interest in recent years. One
technique in particular, known as deep learning, has
produced ground breaking results in many important
problems including image classification and speed
recognition.
Recent growing interest and efforts to incorporate AI
into any number of industries is mainly due to the rise
of deep learning. Also known as deep neural learning or
deep neural network or convoluted neural network
(CNN), it is a type of machine learning algorithm that
uses multiple layers of data for example multiple layers
of image processing to access higher level features from
the image. It is a function of AI which is inspired by the
neurons of the human brain and imitates the functioning
of the human brain in processing data and creating pat-
terns which can be used in decision making. It is capable
of learning unsupervised from data. Deep or convoluted
neural networks are the most used ML techniques in the
biomedical world. These artificial neural networks are
interconnected and follow mathematical models. Their
field of application is vast and allows the management of
‘big data’ in genomics and molecular biology. They are
most commonly applied for analyzing visual images.
Through deep learning, AI recognizes patterns using
various forms of neural networks based on the availabil-
ity of big data repositories. The process is inexpensive
and the computational processing power is easily access-
ible. The neural networks can acquire data rapidly via
image scanners, digital cameras, remote sensors, elec-
tronic appliances or the Internet of Things (IoT). AI has
the ability to learn from both unstructured and un-
labeled data. It uses a hierarchical level of artificial
neural networks to carry out the process of ML. Artifi-
cial neural networks used in AI are built, as mentioned
above, like the human brain with neuron nodes con-
nected together like a web. This is in contrast with trad-
itional computer programs which build analysis with
data in a linear way. The hierarchical design of deep
learning systems enables machines to process data via a
nonlinear approach [1].
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Big data is usually unstructured and is so vast that it
could take years, even decades for humans to under-
stand it, process it and obtain relevant information from
it. The unaided human brain cannot extract meaning
from such vast data sets. Thus, it is necessary to use
computers to identify patterns and associations and
make inferences and predictions from the data. Com-
panies in all spheres and fields have now realized the in-
credible potential of unraveling this wealth of
information and are increasingly adapting to AI systems.
Exponential growth in computing power, data storage
and sensing technology is producing a new world in
which incredible amount of data can be captured and
analyzed.
Owing to the breakthrough of deep learning, AI rap-
idly developed in the 2010s. Utilizing highly advanced
computer processing power and software technology, AI
is expected to radically change our lives, industries and
society as a whole. It has now entered the era of full-
scale practical dissemination.
AI in medicine, the present and the future
Advances in ML algorithms are resulting in the replica-
tion of many medical tasks which currently require hu-
man expertise by AI systems at levels of accuracy similar
to or greater than that achieved by human experts. In
medicine, deep learning applications are increasingly be-
ing trained with large amounts of annotated data sets
freeing medical specialists to focus on more productive
tasks and projects. The potential of AI in medicine is
limitless and can serve as a great boon to improve health
care delivery in clinical practice.
According to Goldenberg et al., computer based de-
cision support systems based on ML have the poten-
tial to revolutionize medicine by performing complex
tasks that are currently assigned to specialists. ML
systems can increase diagnostic accuracy, increase ef-
ficiency of thorough puts, better streamline clinical
workflow, decrease human resource costs and im-
prove treatment choices [2].
However effective use of AI in medicine requires syn-
ergistic transdisciplinary competencies. In medicine, re-
cent promising biomedical and biomarker discoveries
notwithstanding, individually tailored care is still far
from reality and novel therapies which emerge from pre-
clinical trials are very rarely translatable to evaluation
for their diagnostic and therapeutic potential. The dis-
crepancy between experimental data on new anticancer
molecules and their actual use in diagnosis and therapy
is due to a number of factors which include biological
differences between human disease and animal models,
inconsistencies in experimental methodologies, wrong
interpretation of experimental results, lack of validation
of such data by pathologists with long term experience
in animal cancer models etc. For example, personalized
care in oncology requires the synergistic combination of
several disciplines such as nuclear medicine, radiology
and surgical pathology which represent complementary
approaches to diagnosis, prognosis and evaluation of
therapeutic response. A structural collaboration model
between these disciplines can accelerate the achievement
of a medical paradigm which takes into consideration
the uniqueness of every human being. A recent study ex-
amined fifteen papers focusing on early and accurate
diagnosis of breast, lung and prostate cancer and lymph-
oma using innovative AI applications. One example was
the application of a deep neural network in discriminat-
ing between malignant breast cancer lesions in mammo-
graphic images. The authors of this study were confident
that the data they examined provides the scientific ra-
tionale for further investigations in translational medi-
cine based on the combination between surgical
pathology, radiology and nuclear medicine [3].
ML is pioneering a new paradigm for scientific re-
search. Traditionally, the classic ‘hypothesis testing’ ap-
proach is used in research in which processing of data
leads to explanatory mechanisms which then suggest
further experiments that in turn lead to classic findings.
As a result of rapid technological advances, however,
many experiments now collect vast amounts of informa-
tion and can be considered ‘hypothesis generating’. In-
vestigations in genomics and other-omics are cases in
point. The advent of image digitization has led to experi-
ments which generate enormous gigabytes or terabytes
of data. Fortunately, advances in deep learning allow the
derivation of important qualitative and quantitative in-
formation from images, putting visual observation on
the same playing field as molecular analysis. Since deep
learning is also very useful for- omic analysis, it allows
the amalgamation and interpretation of image based
data with – omic information, allowing this data to be
used for providing new and more accurate knowledge.
In this new hypothesis generating paradigm, we hunt for
meaning in a huge data set instead of proceeding one lo-
gical step at a time from observation to better explana-
tions. Thus deep learning has turned the scientific
process on its end [4].
AI has already become a major element in the health
care landscape. It has already become a reality providing
value in many fields of medicine for example in assess-
ment of skin lesions, evaluating fundus retinography for
detection of diabetic retinopathy, radiologic diagnosis for
example interpretation chest radiographs etc. These ex-
amples highlight the value of AI in aiding clinicians to
improve quality, safety, diagnosis and democratization of
care. For example, AI has enable radiologists to read im-
aging studies from anywhere in the world at their own
institution bringing expert care to parts of the world
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where it is not available. In using AI for better medical
care the investment of time and manpower to validate
model data sets is a major hurdle. Because Deep learning
AI identifies patterns, the data used to train the AI
model must be validated by medical specialists. Add-
itional financial resources and considerable time are re-
quired to perfect AI models which can be deployed with
confidence to assist in medical practice.
The question of legal responsibility will need to be re-
solved before AI can become common place in medicine
especially in imaging specialties such as radiology and
pathology. Who will be held accountable for an action
resulting from an AI based decision? Who will be re-
sponsible for an error made through the use of an AI
program? It cannot be emphasized enough that legal re-
sponsibility is a significant consideration in the medical
field when implementing new technologies or proce-
dures or when developing new drugs. Use of AI is new
in medicine and no legal precedents are available. No
matter how much more accurate AI tools are compared
to their human counterparts, the possibility that data
might be misinterpreted through false positive and false
negative findings cannot be excluded. The issue of legal
responsibility for AI based decisions in medicine is fur-
ther complicated and obscured by the lack of clarity and
confusion regarding major issues such as processing of
sensitive personal information and data collection, con-
sent, transparency, storage etc. The human element will
remain an important factor in incorporating AI into
wide practice in hospitals. In pathology, even if the
process is completely automated with a routine digital
imaging system and data base management, human
agreement will likely be essential [5].
Although health care was slow to adopt AI, the pace
of implementation is now accelerating at an impressive
rate. In 2014, the acquisition of AI startups in health
care was about 600 million dollars. In 2021, it is antici-
pated to reach 6.6 billion dollars. One reason health care
is ripe for AI is “big data”. The health care industry has
rich data sets which are ideal for AI [6]. Personalized
care is the major objective of both basic and transla-
tional cancer research. Building an intelligent automated
entity to evaluate, diagnose and treat patients in research
settings is arguably the easiest part of designing an end –
to- end medical AI system. There is a lot of hype and
hopes surrounding emerging AI applications in medicine
but the brittleness of these systems, the importance of de-
fining the correct frameworks for their application and the
need to ensure vigorous quality control including human
supervision to avoid driving patients on ‘autopilot’ towards
unexpected, unwanted and unhealthy outcomes are essen-
tial factors that need to be acknowledged. Since modern
machine learning algorithms perform complex mathemat-
ical transformations to the input data, errors made by
computational systems will require extra vigilance for de-
tection and interpretation [7].
AI will in all probability transform clinical practice
over the next decade. As AI building an intelligent auto-
mated entity to evaluate, diagnose and treat patients in
research settings is arguably the easiest part of designing
an end –to- end medical AI system. There is a lot of
hype and hopes surrounding emerging AI applications
in medicine but the brittleness of these systems, the im-
portance of defining the correct frameworks for their
application and the need to ensure vigorous quality
control including human supervision to avoid driving
patients on ‘autopilot’ towards unexpected, unwanted
and unhealthy outcomes are essential factors that need
to be acknowledged. Since modern machine learning al-
gorithms perform complex mathematical transforma-
tions to the input data, errors made by computational
systems will require extra vigilance for detection and
interpretation [7].
AI will in all probability transform clinical practice
over the next decade. As AI technologies are evolving at
a fast pace and machine learning models are being up-
dated with additional pieces of information, regulatory
approval is essential. Recently, the Food and Drug Ad-
ministration (FDA) announced a pilot certification ap-
proach that inspects both the AI developers and the
product itself [8]. Such steps can ensure public trust in
novel medical AI applications. Even if an AI system is
designed only to advise physicians or health care
personnel rather than to carry out the actual diagnosis
and treatment tasks, it may still result in unintended
harmful consequences. A recent study showed that over-
reliance on decision support systems resulted in in-
creased false negative rate in radiology diagnoses com-
pared with the study scenario when the computer-aided
diagnostic system was unavailable to the same group of
radiologists- this is termed confirmatory bias. In
addition, inexperienced medical practitioners may over-
react to excessive warning messages - this is termed alert
fatigue. Thus, AI developers need to address these chal-
lenges even if the systems only play an advisory role.
Trust in medical technology is closely related to its an-
ticipated utility. If a perception emerges that a new tech-
nology is harmful and has untoward consequences, then
the barriers to its acceptance will become next to insur-
mountable. This issue becomes even more complicated
if the technology is complex and the general public and
even the domain expert cannot fully evaluate its efficacy
and potential hazards. This is termed ‘Frame Problem’.
Frame problem can cause medical errors that will draw
the attention of the public and lead to law suits against
companies or organizations using, deploying or develop-
ing medical AI applications. The ‘black box’ nature (lack
of full disclosure and information about the technology)
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of modern machine learning algorithms may further ex-
acerbate and aggravate the issue. High profile examples
of harmful or inadequate performance will result in
extra scrutiny of the whole field and may hinder the de-
velopment of more robust AI systems. It must be kept in
mind that data driven AI algorithms are not immune
from the ‘garbage - in garbage – out’ rule. ML algo-
rithms are designed to identify the hidden patterns of
the data and generate output projections based on what
they have seen in the past. As many input data sets con-
tain artifacts or biases, the models learnt from such data
carry those biases and can potentially amplify them with
harmful consequences for the patients. Thus, optimized
machine learning models in medicine can be con-
founded by their training data, may not reflect an object-
ive clinical assessment and lead to partiality and
mistakes. Thus, great attention needs to be paid to data
quality and provenance in order to foster ‘patient trust’
in AI systems and to avoid unethical practices even if
only due to negligence. However, this is an expensive
task. In other words, since modern machine learning
algorithms make complex mathematical changes to
the input data, biases and errors made by computa-
tional systems will require extra vigilance to detect
and interpret [9].
Let us now examine various examples of the applica-
tion of AI in various subspecialties of medicine including
gastroenterology, ophthalmology, dermatology, surgery,
radiology, oncology etc. The promise of AI in health care
is the delivery of improved quality and safety of care and
the potential to democratize expertise.
Nakagawa et al. developed a deep learning based AI
system for assessment of superficial esophageal squa-
mous cell carcinoma (SCC). Invasion of tumor depth is
a critical factor which affects the choice of treatment.
However, assessment of cancer depth is subjective and
inter observer variability is common. The authors ob-
tained 8660 non-magnified endoscopic (non-ME) and
5678 ME images as training data set and 405 non- ME
images from 155 patients as validation set. The system
showed sensitivity and specificity of 90.1 and 95.8% re-
spectively and its performance in diagnosing depth of in-
vasion in superficial SCC was comparable to that of
experienced endoscopists [10].
Similarly, Horie et al. developed a deep learning CNN
and tested its ability to diagnose esophageal SCC and
adenocarcinoma. They retrospectively collected 8428
training images of known esophageal carcinoma from
384 patients at their hospital and then prepared 1118
test images from 47 patients with esophageal cancer and
50 patients without cancer to evaluate diagnostic accur-
acy. The CNN took just 27 s to analyze the test images
with a sensitivity of 98%. It detected all cancers less than
10mm in size. The authors were confident that more
training would lead to even greater diagnostic accuracy
thus facilitating early diagnosis with consequent better
prognosis for patients with esophageal cancer [11].
Hirasawa et al. developed a CNN to detect gastric can-
cer in endoscopic images. They trained their CNN-
based diagnostic system using 13,584 endoscopic images
of gastric cancer. To evaluate the diagnostic accuracy, an
independent test set of 2296 images collected from 69
consecutive patients with 77 gastric cancer lesions was
applied to the constructed CNN. The CNN correctly
diagnosed 71 of 77 cancer lesions with an overall sensi-
tivity of 92.2%. 70 of the 71 lesions (98.6%) with a
diameter of 6 mm or more as well as all invasive can-
cers were correctly detected. All missed lesions were
superficially depressed and differentiated – type intra
mucosal cancers that were difficult to distinguish from
gastritis even for experienced endoscopists. Thus, the
system developed by Hirasawa et al. was able to process
numerous stored endoscopic images in a very short
time with a clinically relevant diagnostic ability and
could be applied to daily clinical practice to reduce the
burden of endoscopists [12].
Esteva et al. developed a deep CNN to discriminate
between the most common skin cancers including ma-
lignant melanoma. They compared their algorithm
against 21 board certified dermatologists in evaluating
biopsy proven clinical images and demonstrated at least
equivalent if not outright superiority. The authors sug-
gested that mobile devices, like smart phones, could be
deployed with similar algorithms, permitting potentially
low cost universal access to vital diagnostic care any-
where in the world [13]. Digital pathology is becoming
the new standard of care in dermatology and personal-
ized medicine. This collaboration between dermato-
pathology and dermatology (personalized dermatology)
is aimed at therapy tailored to the specific needs of each
patient [14].
In another recent study, Gulshan et al. applied a deep
CNN approach to a test set of more than 128,000 retinal
fundus images from adult patients with diabetes to iden-
tify referable diabetic retinopathy. The algorithm that
they developed demonstrated a very high sensitivity and
specificity for detecting referable diabetic retinopathy
and macular edema. This study showed that AI will not
be used to replace physicians but rather to perform sim-
ple, cost effective and widely available examinations and
analyses which could help identify at risk patients who
require referral for specialty care while reassuring other
patients that retinopathy was not present [15].
In a recent study, Dong et al. used machine learning
algorithms to predict the disease course of Crohn’s Dis-
ease in Chinese patients. Crohn’s disease is a complex
disease and it is difficult to predict its course. Their pro-
posed machine learning model accurately predicted the
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risk of surgical intervention in their patients. The au-
thors were confident that it could be used to design
treatment strategies tailored to individual Cohn’s Disease
patients [16].
Even in surgery, the same critical question is now be-
ing asked. How will the digital revolution and AI change
surgical practice? How will it translate in the practice of
surgery? A recent study by Wall and Krummel believes
that AI may impact surgery in the near future in three
main areas. These include enhancement of training mo-
dalities, cognitive enhancement of the surgeon and pro-
cedural automation. The authors admit that there have
been unanticipated missteps in the use of these tech-
nologies but have little doubts about their adoption in
surgical practice. The authors agree that the promise of
big data, AI and automation in surgery is high and be-
lieve that surgeons in the near future will need to be-
come “digital surgeons” and must be prepared to adopt
smarter training modalities, supervise the learning of
machines that can enhance cognitive function and ultim-
ately oversee autonomous surgery without allowing for a
decay in their operating skills [17].
AI in radiology, already a success story
In radiology, AI is improving accuracy in diagnostic im-
aging. As patient images can be directly acquired in
digital form for central archival and soft copy review,
radiology practice has readily incorporated AI into clin-
ical practice. An established digital imaging infrastruc-
ture has allowed a seamless embedding of AI into the
radiology workflow. Large amounts of data can be
translated and transmitted within minutes. For patient
images generated by different imaging modalities such
as X-ray, Magnetic Resonance Imaging (MRI), Com-
puted Tomography (CT), ultrasound, and mammo-
gram, deep learning AI can be automated to pinpoint
accurately the areas of interest and diagnosis. Image
recognition using AI with deep learning through
CNNs has dramatically improved and is being in-
creasingly applied for diagnostic imaging [5].
Radiology converted to digital images more than 25
years ago. It is well positioned to deploy AI for diagnos-
tics. Several studies have shown considerable success in
the use of AI for evaluating a variety of scan types in-
cluding mammography for breast lesions, CT scans for
lung nodules and infections and MRI images for brain
tumors. By converting to digital images, radiology elimi-
nated film, chemicals, developers and storage of films
and solved problems related to loss of films and trans-
port of films to where they are needed for example in-
tensive care units (ICUs), operating rooms (ORs) and
emergency departments. There was inherent value
within these images for greater learning using computers
to improve the quality, safety and efficiency of
radiologists. However, the role of radiologist remains
crucial. For example, chest x-ray films with atypical fea-
tures would still need to be reviewed by radiologists to
ensure that artifacts or unusual clinical contexts were
adequately captured. An AI system will need to be con-
tinually calibrated by human feedback.
Lee et al. developed a deep learning based computer-
aided diagnosis (CAD) system for use in diagnosis of
cervical lymph node metastases by CT scan in thyroid
cancer. The authors collected 995 axial CT images (647
benign and 348 malignant) from 202 patients who
underwent CT for planning of surgery. Their system was
able to classify cervical lymph node metastases with a
high degree of accuracy. The authors believe that their
model may be useful in the clinical setting for the above
purpose [18].
A 2019 radiology based study tested the effect of AI in
automatic identification of lung cancer nodules (1mm and
5mm thick) by CT in patients with stage T1 lung cancer
and compared the results with manual screening of T1 lung
cancer nodules by CT. It needs to be understood that using
CT to screen lung cancer nodules is a huge workload. The
AI recognition technology used in the study learned by
computer neural network methods 5000 cases of stage T1
lung cancer patients with 1mm and 5mm thickness nod-
ules. Following this learning, 500 cases of chest CT in stage
T1 lung cancer patients with 1mm and 5mm thickness
nodules were tested with AI and results were compared
with those of artificial manual reading by radiologists. The
detection rates were similar and no significant differences
were noted. Thus, automatic learning of early lung cancer
chest CT images by AI showed high specificity and sensitiv-
ity for early lung cancer identification and may prove in-
valuable in the near future in assisting doctors in the early
diagnosis of small lung cancer nodules [19].
Value of a synergistic approach between disciplines
using AI for cancer prognostication and therapy: AI,
through the use of convolutional networks is also ex-
pected to play an important role in prediction of cancer
outcome. Survival outcome is the most important out-
come for cancer patients so that they can plan for them-
selves and their families. Thus, determining cancer
progress is crucial to controlling suffering and death due
to cancer. As the histologic diagnosis of cancer is an es-
sential initial step in determining the line of therapy, pa-
thologists have a great responsibility in the diagnosis of
cancer. Histologic grading and staging systems based on
the size or extent of invasion of the primary tumor, in-
volvement of regional lymph nodes and presence or ab-
sence of distant metastases are currently used to predict
the biologic behavior of cancer. In addition to histology,
several other tools including genomic markers, gene ex-
pression and epigenetic modifications are also used to
predict outcome in cancer patients [20].
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Since personalized medicine is the main objective of
cancer research, it is essential to form an alliance be-
tween imaging diagnostics (radiology and nuclear medi-
cine) and surgical pathology since a structured
collaboration model between these disciplines can speed
up the achievement of a paradigm for personalized
medicine. A recent study presented automatic glioma
grade identification from MRI images using deep convo-
lutional neural network. Glioma images were collected
from government hospitals and the AI system catego-
rized the tumors into four grades: low grade glioma,
oligodendroglioma, anaplastic glioma and glioblastoma
multiforme. The results showed reasonably good per-
formance with high classification accuracies [21]. An-
other recent study by Mobadersany et al. utilized digital
pathology images and genomic markers to predict over-
all survival of brain tumors. The authors examined the
ability of AI in predicting overall survival in diffuse gli-
omas. Histologic grading and genomic classifications
have independent prognostic power in such predictions.
Until the recent past, histologic diagnosis and grading
were used but the recent emergence of molecular sub-
typing has resolved the uncertainty related to lineage.
Criteria for grading gliomas need to be redefined in the
context of molecular subtyping. Improving the accuracy
and objectivity of glioma grading will directly impact pa-
tient care by identifying patients with aggressive disease
who require more aggressive therapeutic regimens and
sparing those with less aggressive disease from unneces-
sary treatments. Currently, all grade III and IV diffuse
gliomas are typically treated very aggressively with radi-
ation and concomitant chemotherapy. In the above men-
tioned study, the AI software learned about survival
from histologic images and created a unified framework
which interpreted histology and genomic biomarkers for
predicting time to event outcomes. The ability of pre-
dicting patient outcomes by AI was found to be more
accurate than that of surgical pathologists. This study
provides insights into applications of deep learning in
medicine and the integration of histology and genomic
data and provides methods for dealing with factors such
as intratumoral heterogeneity [22]. Similarly, Muneer
et al. used AI techniques for glioma grade identification
and their results were excellent with greater than 90%
accuracy [23]. The clinical success of Immunotherapy is
driving the need to develop new prognostic and predict-
ive assays for patient selection and stratification. This
can be achieved by a combination of computational
pathology and AI. A recent study critically assessed vari-
ous computational approaches which can help in the de-
velopment of a standardized methodology in the
assessment of immune oncology biomarkers such as
PDL-1. The authors discussed how integrated bio in-
formatics allow the amalgamation of complex
morphological phenotypes with AI. They provided an
outline of ML and AI tools which can be applied in
immuno -oncology for example pattern recognition in
large and complex data sets and deep learning ap-
proaches for survival analysis. They were hopeful that
combinations of surgical pathology and computational
analysis will improve patient stratification in immuno –
oncology. The authors are convinced that future clinical
demands will be best met by dedicated research at the
interface of surgical pathology and bio informatics sup-
ported by professional societies and by incorporating
data sciences and digital image analysis in the profes-
sional education of pathologists [24].
AI in oncology
In Oncology, new AI intelligence platforms could in fu-
ture assist in making therapeutic decisions in cancer pa-
tients [25]. In 2016, the results of a double-blind
validation study were presented at the San Antonio
Breast Cancer Symposium which demonstrated a strong
concordance between treatment recommendations by a
panel of oncologists and Watson for oncology (WFO),
an AI platform which was developed by IBM Corpor-
ation, (Armonk, NY) in collaboration with Memorial
Sloan Kettering Cancer Center. WFO computing system
has the ability to extract and assess large amounts of
structured and unstructured data from medical records.
It then uses natural language processing and machine
learning to present cancer treatment options. In this
study, the authors compared the concordance between
WFO and the multidisciplinary tumor board of the insti-
tution (a group of 12 to 15 oncologists). The degree of
concordance was analyzed in 638 patients with breast
cancer who had been treated at the hospital. The time it
took for each method to issue recommendations was
also analyzed. The study showed that 90% of WFO’s rec-
ommendations were concordant with those of the tumor
board. Nearly 80% of the recommendations were con-
cordant in patients with non – metastatic breast cancer.
However, concordance was only 45% in patients with
metastatic disease, 68% in patients with triple negative
breast cancer and 35% in patients with HER 2/neu nega-
tive breast cancer. The authors noted that patients with
triple negative breast cancer have fewer treatment op-
tions compared to those with HER 2/neu negative breast
cancer. More complicated cancers lead to more diver-
gent opinions regarding treatment. The authors found
that it took an average of 20 min to manually capture
and analyze the data and generate recommendations.
However, after the oncologists gained more familiarity
with the cases, the mean time decreased to approxi-
mately 12 min. WFO, on the other hand took only 40 s
to capture and analyze the data and make recommenda-
tions. According to the authors of this study, WFO can
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provide treatment recommendations not only for pa-
tients with breast cancer but also for those with lung
and colorectal cancer. The lead author’s institution in
India recently adopted the WFO system to support on-
cologists in making quality, evidence based treatment
decisions in cancer patients. The study however cau-
tioned that though AI is a helpful step toward personal-
ized medicine, it can only complement the physician’s
work, not replace it. This is because when dealing with
humans, many factors such as the context and prefer-
ence of each patient, the patient-physician relationship,
human touch and empathy are present which cannot be
addressed by a machine [26].
Liu et al. in 2018 published a feasibility study using
WFO to assess its ability to make treatment recommenda-
tions in Chinese patients with lung cancer. In the authors’
own words, “WFO is an outstanding representative AI in
the medical field, and it can provide to cancer patients
prompt treatment recommendations comparable with
ones made by expert oncologists”. WFO is increasingly
being used in China. The authors selected all lung cancer
patients who were hospitalized and received antitumor
treatment for the first time at their hospital. They used
WFO to make treatment recommendations for their pa-
tients and then compared these recommendations to
those made by (or treatment regimens administered by)
their expert multi-disciplinary team. Almost 66% recom-
mendations made by WFO were consistent with the rec-
ommendations made by the oncology experts. They
concluded that though WFO recommendations were con-
sistent with the experts in the majority of cases, they were
still inconsistent in a significantly high proportion of cases
and thus, WFO could not currently replace oncologists.
They asserted that WFO can improve the efficiency of
clinical work by providing assistance to doctors but it
needs to learn the regional, ethnic characteristics of pa-
tients to improve its assistive ability [27].
AI in surgical pathology: its potential and promise,
difficulties and obstacles, current applications and future
directions
More than a decade ago, a number of articles described
in detail the steps by which AI could be applied for rou-
tine tissue based diagnosis using ‘virtual slides’ or in
other words the presentation of microscopic images as a
whole in a digital matrix. These steps include the meas-
urement of individual image quality and its correction if
unsatisfactory, development of a pixel based diagnostic
algorithm and its application in diagnosis and classifica-
tion and feedback to order additional information. Ex-
amples include virtual Immunohistochemical slides,
automated image classification, detection of relevant
image information, and supervision by pathologists.
These early studies hoped that pathologists will no
longer be primary “water carriers” but will work as super-
visors at a “higher level” and AI will allow them more time
to concentrate on difficult cases for the benefit of their pa-
tients. Even in 2009, virtual slides were already in use for
teaching and continuous education and first attempts to
introduce them into routine work had begun. At that time
the implementation of a complete connected AI sup-
ported system was in its childhood [28].
Advances in the quality of whole –slide images have
set the stage for the clinical use of digital images in sur-
gical pathology. Along with advances in computer image
analysis, this raises the possibility for computer assisted
diagnostics in pathology to improve histopathologic in-
terpretation and clinical care.
Pathology was late to adopt digital imaging and com-
puter assisted diagnostic technologies. This is partly due
to practical and financial obstacles. It needs to be under-
stood that unlike radiology, many of the practical bene-
fits cannot be achieved with pathology digitization. A
surgical pathology workflow that includes digital path-
ology will not reduce or remove the need to produce
and ultimately store glass slides. Instead of any reduc-
tions, digital pathology will require additional workflows,
personnel, equipment and importantly storage of data (it
is estimated that digital pathology images constitute at
least ten times larger files than radiology images) all on
top of an already financially and operationally stressed
health care system. Digital pathology will definitely bring
some advantages especially in areas such as rapid tele-
consultations with experts, quality and safety etc. Thus,
proof of definite clinical value will be essential for wide-
spread adoption of digital pathology. Given that digital
pathology is likely to be costlier. AI in pathology will
need to demonstrate improved efficiency, quality and
safety [4, 6].
A major challenge to the deployment of digital path-
ology was recently addressed. In April 2019, Philips re-
ceived FDA clearance for a Pathology Solution to be
used for primary pathology diagnostics. This device is
used for scanning glass pathology slides and for review-
ing these slides on computer monitors. This Pathology
Solution has already been established as a predicate de-
vice that could pave the way for a host of other FDA ap-
proved whole-slide scanners for primary diagnostics to
become available in the coming years. Thus, the expand-
ing role of AI in health care, the reduced costs of digital
data and the availability of usable digital images are now
in alignment for digital pathology to succeed [6].
Telepathology is defined as the practice of routine
pathology using telecommunication links to enable the
electronic transmission of digital pathology images. It
can be used for remotely rendering primary diagnoses,
second opinion consultations, quality assurance, educa-
tion and research. Until recently the use of telepathology
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in clinical patient care was limited mostly to large aca-
demic institutions. In addition to prohibitive costs and
legal and regulatory issues technological problems, lack
of universal standards and most importantly resistance
from pathologists slowed its widespread use. The adop-
tion of telepathology practice is likely to expand in order
the meet the increased demands for subspecialist con-
sultation, and as technology advances, to improve diag-
nostic accuracy and work flow [29].
There are five main categories of digital or (tele) path-
ology i.e. static, dynamic, robotic, whole slide imaging
(WSI) and hybrid methods. Telepathology systems from
any of these categories can be used and have been found
to provide timely and accurate diagnoses similar to con-
ventional microscopy. It is important that these systems
meet clinical needs and are validated for the intended
use. The decision to purchase a particular system will
depend on the clinical application, specific needs and
budget of the laboratory as well as the personal prefer-
ences of the telepathologists involved [30].
In addition, the recent development of tissue clearing
technology introduces the possibility of 3D pathology
which allows for the collection of the 3D context of tis-
sue and would contribute to increased accuracy of auto-
matic pathological diagnosis by machine learning [31].
Automated analysis of histological slides is now possible
through WSI scanners which can acquire and store slides
in the form of digital images. This scanning associated
with deep learning algorithms allows recognition of le-
sions through automatic recognition of regions of interest
previously validated by the pathologist. These computers
aided diagnostic techniques have already been tested in
breast pathology and dermatopathology [32].
A 2016 study tested techniques for preprocessing of
free-text breast cancer pathology reports with the aim of
facilitating the extraction of information relevant to can-
cer morphology, grading and staging. These techniques
included using freely available software to classify the re-
ports as semi-structured or unstructured based on their
general layout, and using an open source language en-
gineering framework to predict parts of the report text
which contained information relevant to the cancer. The
results showed that it was possible to predict the layout
of reports and that the accuracy of prediction as to
which segments of a report contained relevant certain
information was sensitive to the report layout and the
type of information sought [33].
The digital revolution is transforming the practice of
diagnostic surgical pathology by integrating image ana-
lysis and machine learning into routine surgical path-
ology. Thus a clear need is being felt for a robust and
evidence based framework in which to develop these
new tools in a collaborative manner that meet regulatory
approval. A number of regulatory steps have been
approved and implemented by the FDA in the United
States and the NCRI Cellular Molecular Pathology (CM-
Path) initiative and the British In Vitro Diagnostic Asso-
ciation (BIVDA) in the United Kingdom. These bodies
have set out a road map to help academia, industry and
clinicians develop new software tools to the point of ap-
proved clinical use. A 2019 study compared two com-
monly used CNNs in surgical pathology because it is
often assumed that the quality and format of the training
image as well as the number of training images in differ-
ent convolutional networks impacts the accuracy of
diagnosis. The authors photographed 30 hematoxylin
and eosin (H&E) stained slides with normal tissue or
carcinoma from breast, colon and prostate generating
3000 partially overlapping images (1000 per tissue type).
They found that the images from the two convolutional
networks were similar in their accuracy and large num-
bers of unique H&E stained slides were not required for
training optimal ML models in diagnostic surgical path-
ology. The authors reinforced the need for an evidence
based approach by comparing different ML models in
order to achieve the best practices for histopathological
ML ensuring an accurate diagnosis [34, 35]. Added value
of quantitative AI in pathology includes the confirmation
of equivocal findings noted by a pathologist, increasing
sensitivity of feature detection, improving efficiency etc.
Role of AI in surgical pathology in poor countries
Many authorities believe that there is no denying that
quantitative AI is part of the future of pathology. How-
ever, the significant cost issues involved may be cur-
rently prohibitive for poor, developing countries. In
these countries, the focus on ‘telepathology’ as a possible
solution will be inadequate. Incorporating AI in tele-
pathology can provide temporary solutions until requis-
ite financing schemes are implemented. AI is especially
applicable to surgical pathology because diagnosis de-
pends on pattern recognition which is a useful quality
for digital applications that depend on machine learning.
AI has the potential to create online data repositories
that can be used for the diagnosis of pathological speci-
mens (e. g breast cancer) worldwide, greatly reducing
human and infrastructural resource burden. A recent
study showed that machine learning algorithms achieved
potentially faster and more accurate diagnoses than 11
pathologists in a simulated setting. It is obvious that in-
corporation of AI in telepathology will demand high re-
sources and entail heavy costs. These issues could be
directly addressed if value is clearly demonstrated and
results in government and third-party payers investing
in reimbursement strategies for its use in pathology. The
recognition of AI as part of reimbursement strategies
that reward value-based care would provide important
incentives to develop and implement validated
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algorithms. In developed western countries, the private
sector is showing interest in investing in AI and other
new technologies in healthcare. AI incorporation in
pathology should be explored as a bold and creative idea
in developing countries to motivate investment by
private sector. The global efforts currently going on
towards developing sustainable pathology and labora-
tory medicine services in low and middle income
countries should include AI in pathology especially
surgical pathology [29, 30, 34, 36].
However, other authorities disagree, at least in the
context of surgical pathology. Some believe that al-
though AI will play some role in diagnosis in the future,
it could actually detract attention from proven, basic in-
vestments that are necessary to provide access to path-
ology and laboratory medicine services in low and
middle income countries (LMICs). They argue that the
use of AI in surgical pathology is still in its infancy and
its ability to generate accurate diagnoses is yet to be
proven. They believe that AI in telepathology will only
be implemented in LMICs if it has first been successfully
implemented in high income countries (HICs) where
currently its role in day to day patient care remains un-
clear. These authors further argue that although tele-
pathology could be used within integrated, tiered
laboratory networks in LMICs, with slides prepared and
scanned in lower levels and transferred to higher levels
within the network for interpretation and consultation,
telepathology relies on access to technology that is nei-
ther affordable nor practical in these countries. Most
LMICs even lack the capacity to generate the slides
needed as a prerequisite for telepathology and do not
have access to these integrated networks. Even if it was
affordable and possible to develop histopathology ser-
vices, implement telepathology systems and transmit im-
ages taken in LMICs to pathologists in HICs as a
temporary solution, there are insufficient numbers of pa-
thologists in HICs to interpret images for large numbers
of patients even in their own countries [37].
Will AI replace microscopes and pathologists? Not-
withstanding the many difficulties and obstacles, it is
now widely accepted that the use of AI will transform
clinical practice over the next decade and some authors
believe that an early impact of this will likely be the inte-
gration of image analysis and ML into routine surgical
pathology. With a digital revolution transforming the
reporting practice of diagnostic surgical pathology, a
proliferation of image analysis software tools has re-
sulted worldwide. This has ignited a hot debate among
pathologists whether with increasing availability and re-
finement of image analysis software, surgical pathologists
will ultimately be replaced by computer algorithms. In
other words, will AI algorithms and computer programs
replace pathologists and what therefore is the future of
surgical pathologists? It is already widely accepted that
AI algorithms “will be incredibly useful in medical re-
search, diagnosis (and) complex treatment planning”.
Currently, there appear to be many hurdles to replacing
human microscopists with computer algorithms. On the
practical side, as discussed previously there are signifi-
cant financial barriers and costs to incorporating slide
scanners and computers into pathology workflow, al-
though presumably hospitals would undertake these
steps if it was proved that computer algorithms im-
prove diagnostic accuracy or increase the efficiency of
pathologists [5, 38].
An especially important and interesting question is: will
computer algorithms surpass humans in diagnostic abil-
ities? Some authorities are skeptical and believe that not-
withstanding the success of AI in radiology and
cardiology, it is at present difficult to envision how AI can
be integrated effectively into routine pathology practice.
Pathology departments generate high resolution micros-
copy images which unlike radiology and cardiology do not
correlate to equivalent standardized digital imaging for-
mats and workflows. Images in pathology require a man-
ual process of tissue biopsy, specimen preparation and
staining before digitization. Currently, development of
such state - of - the - art computer vision algorithms re-
quires millions of training images. Although WSI which
involves scanning the whole tissue on glass slides and
digitizing the images is useful and allows many pathology
slides to be analyzed efficiently within a relatively short
period of time, the system nevertheless suffers from com-
plications associated with acceptance, speed, the ability to
digitize all types of tissues as well as issues of data reso-
lution, storage and regulation. More importantly, estab-
lishing a whole slide image database of millions of images
is currently not practical. Although there are research pro-
jects experimenting with digitized pathologic images, there
is currently no standardized digital pathologic imaging
workflow. Another problem is the size of data. It is cur-
rently impossible to directly feed whole slide images into
algorithms because each one contains about 10GB of data.
However newer studies have demonstrated a promising
approach to circumvent this problem by dividing whole
slide images into smaller patches and then training an al-
gorithm to classify these patches into different categories.
Once this is done, statistical summaries of patch diag-
nosis are fed into a machine learning algorithm to
classify the entire image into a single diagnosis. Re-
cent studies have shown that algorithms developed in
this way are able to distinguish subtypes of non –
small cell carcinoma of lung with an accuracy similar
to that of expert pulmonary pathologists. In breast
cancer, combining the predictions of human patholo-
gists and algorithms led to an 85% decrease in human
error in detecting metastatic breast cancer [5, 39–41].
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In 2017, FDA approved the first WSI system which may
encourage the pathology community to begin standardiz-
ing and using digitization on a larger scale thereby stream-
lining the exchange of information. The multidimensional
nature of radiology or cardiology images allows them to
be viewed on a 2 or 3 or 4 dimensional plane which pro-
vides rich information via AI pattern recognition. On the
other hand, pathology images are digitized for 2 dimen-
sional imaging of the sample which does not provide as
much information as it would on a 3 or 4 dimensional
plane. Currently, in the absence of standardized pathologic
imaging workflow, the exchange and translation of infor-
mation to other information systems, physicians and
health systems is very difficult. Large centralized image ar-
chives of digitized pathologic images are not accessible
compared to other medical imaging archives creating add-
itional obstacles to the successful integration of AI into
pathology practice. The development of such large cen-
tralized image archives or databases will require immense
capital investment which may not be feasible for smaller
hospitals. Thus even assuming that high speed AI algo-
rithms can be developed to accurately detect and diagnose
digitized pathology images, the gain in productivity from
automation may be low in the face of the immense finan-
cial costs involved. One viable solution to this problem
may be pathologic imaging management in the cloud
computing environment provided adequate security priv-
acy issue safeguards are ensured and the speed of image
transfer over the internet is sufficient. If these are success-
ful and a standardized digital imaging infrastructure in
pathology is established, it will allow AI to become a
powerful asset to pathologists who seek to better bridge
the gap between research and patient care. In the near fu-
ture, it is likely that technological advances like highly effi-
cient automated whole slide scanner systems, innovative
AI platforms, and pathologist friendly image annotation
and analysis systems will become increasingly prominent
in the daily professional lives of pathologists [5].
Many authors now predict that computers will become
increasingly integrated into the pathology work flow and
will especially be useful when they can improve accuracy
in answering questions which are difficult for patholo-
gists. It is predicted that computer programs i will be
able to count mitotic figures or quantitatively grade im-
munohistochemistry stains more accurately than pathol-
ogists and could identify regions of interest in
cytopathology slides thus reducing the time a pathologist
would need to spend in screening. Some authors also
predict that, over time, as computers gain more and
more discriminatory abilities, they will reduce the
amount of time it takes for pathologists to render diag-
noses and in the process reduce the demand for patholo-
gists as microscopists potentially enabling pathologists
to focus their cognitive resources on higher level
diagnostic and consultative tasks such as integrating mo-
lecular, morphologic and clinical information to assist in
treatment and clinical management decisions for indi-
vidual patients, in other words on personalized care. It is
predicted that digital pathology, WSI and AI will be syn-
ergistic technologies to human cognition. The question
of “human versus computer” is already being refined to
“human versus human with computer”. It is believed
that AI will enable pathologists to focus more on higher
level cognitive tasks by performing the repetitive detailed
tasks which require accuracy and speed and which
humans find mind-numbing and consequently error
prone. Pathologic diagnosis is considered to be a well-
thought-out cognitive opinion, benefiting from the pa-
thologists’ training and experience and subject to their
biases. It is argued that the professional value of patholo-
gists comes from their ability to give the most appropri-
ate (even if not the most perfect) opinion in the clinical
context and that human pathologists constantly recali-
brate their diagnosis based on even small but significant
bits of clinical and patient specific information provided
through physician notes, pathology reports, verbal or
written communications with clinicians etc. It is believed
by many authors that a person working in partnership
with an information resource is better than that same
person unassisted. In other words, they favor “human
versus human with computer” rather than “human ver-
sus computer”. They believe that a sunny era of AI as-
sistance in pathology is on the horizon and do not
believe in dark clouds of AI competition replacing pa-
thologists. However, at the same time, they are realistic
enough to recognize that eventually even the cognitive
lead of human pathologists will narrow as new and bet-
ter AI products emerge. Currently the whole frame work
of AI, digital pathology and WSI depends on financial
factors and remains undefined. It may, ironically, depend
on human ability to overcome financial, technological
and regulatory obstacles [42, 43].
Education of pathologists will be the greatest challenge
and will require the longest times. AI methods will need
to be integrated into all pathology training programs.
Future generations of pathologists will need to be com-
fortable using digital images and other data in combin-
ation with computer algorithms in their daily practice.
Optimistically, 5 to 10 years will be required to build
such a work force even in developed countries and that
too only if the process begins now. Many believe that AI
may be just what pathology has been waiting for. While
still requiring evaluation within a normal surgical path-
ology workflow, deep learning has the opportunity to as-
sist pathologists by improving the efficiency of their
work, standardizing quality and providing better prog-
nostic information. Like in the case of immunohisto-
chemistry and molecular diagnostics, there is little risk
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of pathologists being replaced. Although their work-
flow will likely change, their contribution to patient
care will continue to be critically important. The
diagnostic process is too complicated and diverse to
be trusted to hard-wired algorithms alone. It is hoped
that AI and human pathologists will be natural coop-
erators, not natural competitors. Thus, it appears AI
will not replace the microscopist or take over path-
ology anytime soon. The hypothesis that intuition and
creativity combined with the raw computing of AI
heralds an age where well designed and executed AI
algorithms will solve complex problems and replace
the microscopist are not true. The microscope will
probably be around for a long time. However, AI will
likely play an increasingly important role in diagnostic
microscopy. In the words of Granter et al., “winter
may be coming but hopefully it will be gentle and
mild.” [6, 38, 42].
Current applications of AI in pathology
Let us now examine various examples of application of
AI in practical surgical pathology especially in cancers
and its impact on patient care.
As far back in 2007, Wild et al. used AI to predict the
risk of progression to muscle invasion in non-muscle in-
vasive bladder cancers. They integrated urinary bladder
cancer arrays with artificial neural networks for this pur-
pose. Although the recurrence rate of non-invasive blad-
der cancer is high, the majority of tumors are indolent
and can be managed by endoscopic means alone. On the
other hand, the prognosis of muscle invasion in bladder
cancer is poor and radical treatment is required if cure
is to be obtained. The authors developed a predictive
panel of 11 genes to identify tumor progression. They
found that the combination of genes analyzed using arti-
ficial neural networks was able to significantly stratify
risk of tumor progression which was very difficult to
identify by clinicopathological means [44].
In lung cancer, computational analysis of histological
images using AI is now being increasingly applied in
order to improve the diagnostic accuracy. Tumor pheno-
type usually reflects the overall effect of molecular alter-
ations on the behavior of cancer cells and provides a
practical visual reading of the aggressiveness of the
tumor. However, in some cases, the human evaluation of
histological images is subjective and lacks reproducibil-
ity. AI is now being increasingly used in routine clinical
practice for the optimization of histological and cyto-
logical classification, prognostic prediction and genomic
profiling of patients with lung cancer. However, there
are still several challenges which need to be addressed
for successful utilization of AI in the accurate diagnosis
and prognostication of lung cancer [45].
Histopathological assessment of lung cancer slides is
usually accurate in reaching a correct diagnosis. How-
ever, the prediction of prognosis is not very accurate. In
a 2016 study, Yu et al. used fully automated microscopic
pathology image factors to predict the prognosis of non-
small cell lung cancer. They obtained 2186 H&E stained
whole slide images of lung adenocarcinoma and squa-
mous cell carcinoma patients from The Cancer Genome
Atlas (TCGA) and an additional 294 histological images
from Stanford Tissue Array (STA) database. From these
images, they extracted 9879 quantitative image features
and selected the top features by using regularized ma-
chine learning methods. They were able to distinguish
short term survivors from long term survivors in pa-
tients with stage I adenocarcinoma and squamous cell
carcinoma and showed that automatically derived image
features can predict the prognosis of lung cancer pa-
tients accurately. Their findings were statistically signifi-
cant. The authors are confident that their methods are
extensible to histopathology images of cancers from
other organs [39].
In a 2018 study, Kumar et al. built an automatic in-
formatics methodology capable of identifying statistically
significant associations between clinical findings of non-
small cell lung cancers (NSCLC) in unstructured texts of
patient pathology reports and the various clinically ac-
tionable genetic mutations identified from next gener-
ation sequencing (NGS) in NSCLC (EGFR, KRAS, BRAF
and PIK3CA). Their findings were statistically significant
(p-value < 0.05) and showed associations to mutations in
specific genes which were consistent with published lit-
erature. Like Yu et al., Kumar et al. were also confident
that their approach is extensible to other cancers and
provide the first steps toward understanding the role of
genetic mutations in the development and treatment of
different types of cancer [40].
Considerable work utilizing AI has already been done
in breast cancer pathology. In breast cancer, the most
common malignancy in women worldwide, earlier diag-
nosis and better adjuvant therapy have substantially im-
proved patient outcome in recent decades. Although
pathological diagnosis has proved to be instrumental in
guiding breast cancer treatment, new challenges have
emerged as increased understanding of breast cancer in
the last few years has revealed its complex nature. As pa-
tient demand for personalized breast cancer therapy
grows, there is an urgent need for more precise bio-
marker assessment and more accurate histologic diagno-
sis to make better therapy decisions. The digitization of
pathology data has opened the door to faster, more re-
producible and more precise diagnosis through comput-
erized image analysis. Software to assist diagnostic
breast pathology through image processing techniques
have been around for years. But recent breakthroughs in
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AI promise to fundamentally change the way breast can-
cer is detected and treated in the near future [46].
Nodal metastasis of breast cancer, or any other cancer
for that matter, influences therapy decisions. Identifica-
tion of tumor cells in lymph nodes can be laborious and
error prone especially for small tumor foci. Steiner et al.
developed a deep learning algorithm for the detection of
breast cancer metastases in lymph nodes. In this study,
six pathologists reviewed 70 digitized slides from lymph
node sections unassisted and assisted by algorithms. In
the assisted mode, the deep learning algorithm was used
to identify and outline regions with high likelihood of
containing tumor. Algorithm assisted pathologists dem-
onstrated higher accuracy than either the algorithm or
the pathologist alone. In particular, algorithm assistance
significantly increased the sensitivity of detection for mi-
cro metastases (91% vs 83%, p-value = 0.02). Average re-
view time per image was also significantly shorter with
assistance than without assistance for both micro metas-
tases and negative images (p-value = 0.002 and 0.018 re-
spectively). The pathologists were asked to provide a
numeric score regarding the difficulty of each image
classification. On the basis of this score, pathologists
considered the image review of micro metastases to be
significantly easier when interpreted with assistance (p-
value = 0.0005). This study demonstrates the potential of
a deep learning algorithm to improve pathologist accur-
acy and efficiency in a digital pathology workflow [47].
In a 2017 study, Yala et al. developed a machine learn-
ing model to extract pertinent tumor characteristics
from breast pathology reports which enabled them to
create a large database. Their system was trained to ex-
tract 20 separate categories of information. They trained
their system from two data sets which consisted of 6295
and 10,841 manually attenuated reports. It is important
to note that extracting information manually from elec-
tronic medical records is a time-consuming and expen-
sive process. The authors tested the accuracy of their
model on 500 reports that did not overlap with the
training set. The model achieved accuracy of 90% for
correctly parsing all carcinoma and atypia categories for
a given patient. The average accuracy for individual cat-
egories was 97%. Using this classifier, they created a
database of 91,505 breast pathology reports from which
information was extracted. They also developed a user –
friendly interface to the data base that allows physicians
to easily identify patients with target characteristics. The
authors believe that their model has the potential to re-
duce the effort required for analyzing large amounts of
data from medical records and to minimize the cost and
time required to extract scientific information from
these data [48].
In a 2018 study, Bychkov et al. developed and trained
a deep learning network to predict outcome of colorectal
cancer based on images of tumor tissue samples.
They evaluated a set of digitized H&E stained tumor
tissue microarray (TMA) samples from 420 colorectal
cancer patients with known clinicopathological and
outcome data. Their results showed that deep learn-
ing based outcome prediction with only small tissue
areas as input outperformed visual histological assess-
ment performed by human experts in stratification of
patients into low risk and high risk categories. They
suggested that state –of-the-art deep learning tech-
niques can extract more prognostic information from
the tissue morphology of colorectal cancer than an
experienced human observer [49].
Yoshida et al. in a 2018 study evaluated the classifica-
tion accuracy of a newly developed e – Pathologist
image analysis software in gastric biopsies. They ob-
tained and stained 3062 consecutive gastric biopsy speci-
mens and digitalized the specimen slides. Two
experienced gastrointestinal pathologists evaluated each
slide for histological diagnosis. The authors compared
the three tier (positive for carcinoma or suspicion of car-
cinoma; caution for adenoma or suspicion of a neoplas-
tic lesion; or negative for a neoplastic lesion) or two –
tier (negative or positive) classification results of human
pathologists with the e-Pathologist. Overall concordance
rate was 55.6%. For negative specimens, concordance
rate was 90.6% but for positive biopsy specimens,
concordance rate was less than 50%. For the two tier
classification, sensitivity and specificity were 89.5 and
50.7% respectively. The authors concluded that al-
though there are limitations to the application of au-
tomated histopathological classification of gastric
biopsy specimens in the clinical setting, the results
show promise for the future [50].
The shortage of well – annotated pathology image
data for training deep neural networks is currently a
major issue because of the high costs involved. To over-
come this, transfer learning techniques are generally
used to reinforce the capacity of deep neural networks.
In order to further boost the performance of the state-
of-the-art deep neural networks and overcome the insuf-
ficiency of well annotated data, Qu et al. presented a
novel stepwise fine tuning-based deep learning scheme
for gastric pathology image classification. Their pro-
posed scheme proved capable of making the deep neural
network imitating the pathologist’s professional observa-
tions and of acquiring pathology – related knowledge in
advance but with very limited extra cost in data annota-
tion. They conducted their experiments with both well-
annotated gastric pathology data and the proposed
target-correlative intermediate data on several state-of-
the art deep neural networks. Their results demonstrated
the feasibility and superiority of their proposed scheme
for boosting the classification performance [51].
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A recent study by Liu et al. evaluated the application
and clinical implementation of a state-of-the-art deep-
learning-based AI algorithm. (Lymph Node Assistant or
LYNA) for detection of metastatic breast cancer in senti-
nel lymph node biopsies. They obtained whole slide im-
ages from H&E stained lymph nodes from 399 patients
(publicly available Camelyon 16 challenge data set).
LYNA was developed by using 270 slides and evaluated
on the remaining 129 slides. The findings were com-
pared with 108 slides (86 blocks) from 20 patients ob-
tained from an independent laboratory using a different
scanner to measure reproducibility. LYNA achieved a
slide-level area under the receiver operating characteris-
tic (AUC) of 99% and a tumor level sensitivity of 91%. It
was not affected by common histological artifacts such
as poor staining, air bubbles or over fixation. The AI al-
gorithm exhaustively evaluated every tissue patch on a
slide and achieved higher tumor-level sensitivity than,
and comparable slide-level performance to, pathologists.
This study once again showed that AI algorithms may
improve the pathologist’s productivity and reduce the
number of false negatives associated with morphologic
detection of tumor cells. The authors provide a frame
work to aid practicing pathologists in assessing AI algo-
rithms for adoption into their workflow (akin to how a
pathologist assesses immunohistochemistry results) [52].
An International contest was held recently to have a
machine detect sentinel lymph node metastases of breast
cancer. It was termed the CAMELYON 16 grand chal-
lenge (Cancer Metastases in Lymph Nodes Challenge)
and different teams submitted deep learning algorithms
for this purpose. The findings of AI algorithms were
compared with those of a panel of 11 pathologists with
varying degrees of expertise in breast pathology. Al-
though the top algorithms performed better than the 11
pathologists when they were under time constraint, they
did not perform differently from the pathologists when
the latter had unlimited time. However, the fact that the
algorithms detected nodal micro metastases at the same
rate or better than pathologists was exciting. The fact
that pathologists were able to do as well or even better
than the algorithms when there were no time constraints
is significant. The CAMELYON 16 challenge highlights
a significant opportunity for AI in pathology, namely
assisting pathologists with screening for lesions [53].
In surgery for laryngeal carcinoma, preservation of ad-
jacent healthy tissue is very important. Thus, accurate
and rapid intraoperative histology of laryngeal tissue is
critical to achieve optimal surgical outcomes. Zhang
et al. used deep-learning based Stimulating Raman Scat-
tering (SRS) microscopy to provide accurate automated
diagnosis of laryngeal squamous cell carcinoma on fresh
surgical specimens without fixation, sectioning, staining
or processing. The authors demonstrated near perfect
concordance between SRS and standard histology evalu-
ated by pathologists. Their deep learning based SRS clas-
sified 33 surgical specimens with 100% accuracy. The
authors contended that SRS histology integrated with
deep learning algorithms has the potential for providing
rapid intraoperative diagnosis which could help in the
surgical management of laryngeal carcinoma [54].
Yadav et al. recently showed how AI is optimizing the
detection and management of prostate cancer through
integration of machine learning based identification of
Gleason scores from pathology slides with genomics, im-
aging (especially MRI) and biomarkers [55].
It is predicted that the laboratory of the future will be
more highly automated and dominated by robotics and
will be more connected to take advantage of the benefits
of AI and the Internet of Things [56].
Conclusion
AI, the theory and development of computer systems
which can perform tasks which normally require human
intelligence, is slowly becoming part of everyday modern
life. Health care was slow to embrace AI but the pace of
implementation has now picked up. Computer based de-
cision support systems based on Machine Learning can
perform complex tasks which are currently assigned to
specialists. This has the potential to revolutionize medi-
cine by increasing diagnostic accuracy, improving clin-
ical workflow, decreasing costs of human resources and
improving therapeutics. Growing interest in AI and ma-
chine learning in diverse industries including health care
is mainly due to the rise of Deep Learning, a process
through which AI recognizes patterns using various
forms of neural networks which resemble the human
brain and which are in turn based on the availability of
big data repositories. The promise of AI in health care is
to deliver improved quality and safety of care and to
democratize expertise through use of mobile devices
such as smart phones which can be deployed with algo-
rithms and potentially be accessible universally at low
cost anywhere in the world delivering vital diagnostic
care. Health care is ripe for AI because it has rich data
sets (big data) which are ideal for AI since computers re-
quire large data sets to learn. AI is thus fast becoming a
major element in the health care landscape. AI algo-
rithms will in the coming future play an important role
in predicting cancer outcome and assisting in thera-
peutic decisions for cancer patients. In fields like radi-
ology which has already embraced digital operations, an
AI revolution is already in progress. Deep neural net-
works will be able to provide a synergistic combination
of disciplines such as radiology, nuclear medicine and
surgical pathology which will hopefully allow the
achievement of a medical paradigm which recognizes
that every human being is unique. Although pathology
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especially surgical pathology was late to adopt AI, mainly
due to practical and financial obstacles, and will require
resources for additional workflows, personnel, equip-
ment, storage of data, the time is now ripe, with rapid
development of new and better AI technology at lower
cost (reduced costs of digital data and availability of
digital images) for AI to succeed in surgical pathology.
Various studies cited above demonstrate the increasingly
effective role of AI in surgical pathology. By increasing
speed and accuracy of diagnosis and by improving prog-
nostication, use of AI is translating into better patient
care. AI will, in the near future, not replace pathologists
but by performing routine repetitive tasks quickly and
accurately, allow pathologists to give time to more com-
plex cognitive tasks and enable them to play a much
greater and effective role in cancer prognosis and thera-
peutics. Thus pathologists need to embrace AI and de-
rive benefit from it by training themselves. This will
require considerable time as AI methods will need to be
integrated into pathology training programs and pathol-
ogists will need to be comfortable using digital images
and data with computer algorithms in their daily prac-
tice. With regulatory control also being established by
government agencies in many countries such as US and
UK, the reliability of AI and the trust of the general pub-
lic will increase substantially and help in better care of
patients which is the prime purpose of all efforts to im-
prove medical technology. In this context, the synergistic
collaboration between fields such as oncology, radio
diagnostics and surgical pathology will play a major role.
Financial barriers will need to be overcome especially for
poor developing countries so that they can also benefit
from improvements in AI application in medicine and
pathology.
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